



Veritas In Silico Inc.,


Small and medium size molecule drugs targeting mRNAs will bring innovative new therapies to unmet medical needs

We, Veritas In Silico Inc (VIS) , are focusing on establishment of drug discovery platforms generating small and medium size molecules to reduce translation levels of *any* specific mRNAs just like siRNAs or antisense oligo nucleotides (ASOs) do.

VIS' proprietary technologies are not limited to drug design of small and medium size molecules but also positive controls for in vitro screening and cell-based assay. VIS will apply these technologies to our internal programs and provide these to valued customers.

Drug Discovery: drug molecules targeting specific mRNA motifs

Endogenous motifs stabilized by small molecules will elicit "ribosomal stalls".



"Ribosome stalls" will initiate NO-Go Decay process to decompose mRNAs containing the motifs.

Cosmetics, food, medical supplies and the biotechnology system